Xavier de Lamballerie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1386910/publications.pdf

Version: 2024-02-01

144 papers 10,524 citations

41344 49 h-index 96 g-index

158 all docs

158 docs citations

158 times ranked 15270 citing authors

#	Article	IF	CITATIONS
1	Humoral response after SARS-CoV-2 vaccination in patients undergoing maintenance haemodialysis: loss of immunity, third dose and non-responders. Nephrology Dialysis Transplantation, 2022, 37, 390-392.	0.7	14
2	Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. Antiviral Research, 2022, 197, 105212.	4.1	9
3	Immunoglobulin M seroneutralization for improved confirmation of Japanese encephalitis virus infection in a flavivirus-endemic area. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, 116, 1032-1042.	1.8	3
4	The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model. Communications Biology, 2022, 5, 225.	4.4	10
5	A simple reverse genetics method to generate recombinant coronaviruses. EMBO Reports, 2022, 23, e53820.	4.5	15
6	Widespread interspecific phylogenetic tree incongruence between mosquito-borne and insect-specific flaviviruses at hotspots originally identified in Zika virus. Virus Evolution, 2022, 8, veac027.	4.9	2
7	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200413119.	7.1	110
8	Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2. EBioMedicine, 2022, 82, 104148.	6.1	8
9	Development and characterization of recombinant tick-borne encephalitis virus expressing mCherry reporter protein: A new tool for high-throughput screening of antiviral compounds, and neutralizing antibody assays. Antiviral Research, 2021, 185, 104968.	4.1	9
10	Evidence of early circulation of SARS-CoV-2 in France: findings from the population-based "CONSTANCES―cohort. European Journal of Epidemiology, 2021, 36, 219-222.	5.7	54
11	Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates. PLoS Neglected Tropical Diseases, 2021, 15, e0009300.	3.0	6
12	Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nature Communications, 2021, 12, 1735.	12.8	105
13	SARS-CoV-2 viral dynamics in non-human primates. PLoS Computational Biology, 2021, 17, e1008785.	3.2	41
14	Diagnostic performance of anti-Zika virus IgM, IgAM and IgG ELISAs during co-circulation of Zika, dengue, and chikungunya viruses in Brazil and Venezuela. PLoS Neglected Tropical Diseases, 2021, 15, e0009336.	3.0	7
15	Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population. Infectious Diseases Now, 2021, 51, 380-382.	1.6	28
16	Spike and neutralizing antibodies response to COVID-19 vaccination in haemodialysis patients. CKJ: Clinical Kidney Journal, 2021, 14, 2239-2245.	2.9	12
17	Emergence of Indian lineage of ECSA chikungunya virus in Djibouti, 2019. International Journal of Infectious Diseases, 2021, 108, 198-201.	3.3	4
18	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, 2021, 6, .	11.9	357

#	Article	IF	CITATIONS
19	2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2021, 166, 3513-3566.	2.1	62
20	Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2. Antiviral Research, 2021, 193, 105137.	4.1	32
21	Favipiravir Inhibits Mayaro Virus Infection in Mice. Viruses, 2021, 13, 2213.	3.3	2
22	Zika Virus Seroprevalence in Two Districts of Chincha, Ica, Peru: A Cross-Sectional Study. American Journal of Tropical Medicine and Hygiene, 2021, , .	1.4	1
23	Model-based assessment of Chikungunya and O'nyong-nyong virus circulation in Mali in a serological cross-reactivity context. Nature Communications, 2021, 12, 6735.	12.8	4
24	Long-Term Infectivity of Chikungunya Virus Stored in the Dark at 4°C. Vector-Borne and Zoonotic Diseases, 2021, 21, 989-993.	1.5	2
25	A Report of Zika Virus Seroprevalence in Republic of the Congo. Vector-Borne and Zoonotic Diseases, 2020, 20, 40-42.	1.5	5
26	Recombination of B- and T-cell epitope-rich loci from Aedes- and Culex-borne flaviviruses shapes Zika virus epidemiology. Antiviral Research, 2020, 174, 104676.	4.1	11
27	Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. Antiviral Research, 2020, 181, 104880.	4.1	121
28	Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature, 2020, 585, 584-587.	27.8	287
29	2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2020, 165, 3023-3072.	2.1	184
30	Vector-Borne Transmission of the Zika Virus Asian Genotype in Europe. Viruses, 2020, 12, 296.	3.3	10
31	Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates. Antiviral Research, 2020, 177, 104758.	4.1	10
32	Of chloroquine and COVID-19. Antiviral Research, 2020, 177, 104762.	4.1	468
33	Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 258-271.	2.5	20
34	A need to raise the bar $\hat{a} \in \mathcal{C}$ A systematic review of temporal trends in diagnostics for Japanese encephalitis virus infection, and perspectives for future research. International Journal of Infectious Diseases, 2020, 95, 444-456.	3.3	17
35	The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers. PLoS Neglected Tropical Diseases, 2020, 14, e0008259.	3.0	13
36	Dose Rationale for Favipiravir Use in Patients Infected With SARS oVâ€2. Clinical Pharmacology and Therapeutics, 2020, 108, 188-188.	4.7	34

#	Article	IF	CITATIONS
37	Zika Virus Circulation in Mali. Emerging Infectious Diseases, 2020, 26, 945-952.	4.3	11
38	Reverse Genetics of RNA Viruses: ISA-Based Approach to Control Viral Population Diversity without Modifying Virus Phenotype. Viruses, 2019, 11, 666.	3.3	9
39	Seroprevalence Study of Anti-HEV IgG among Different Adult Populations in Corsica, France, 2019. Microorganisms, 2019, 7, 460.	3.6	13
40	Evolution and biological significance of flaviviral elements in the genome of the arboviral vector <i>Aedes albopictus</i> . Emerging Microbes and Infections, 2019, 8, 1265-1279.	6.5	7
41	A New High-Throughput Tool to Screen Mosquito-Borne Viruses in Zika Virus Endemic/Epidemic Areas. Viruses, 2019, 11, 904.	3.3	16
42	Detection of a Novel Phlebovirus (Drin Virus) from Sand Flies in Albania. Viruses, 2019, 11, 469.	3.3	9
43	An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus for Mice. Journal of Virology, 2019, 93, .	3.4	30
44	Assessing Zika Virus Transmission Within Households During an Outbreak in Martinique, 2015–2016. American Journal of Epidemiology, 2019, 188, 1389-1396.	3.4	9
45	Management of Central Nervous System Infections, Vientiane, Laos, 2003–2011. Emerging Infectious Diseases, 2019, 25, 898-910.	4.3	29
46	Nasal or throat sampling is adequate for the detection of the human respiratory syncytial virus in children with acute respiratory infections. Journal of Medical Virology, 2019, 91, 1602-1607.	5.0	6
47	Viral RNA Degradation Makes Urine a Challenging Specimen for Detection of Japanese Encephalitis Virus in Patients With Suspected CNS Infection. Open Forum Infectious Diseases, 2019, 6, ofz048.	0.9	7
48	Zika virus threshold determines transmission by European <i>Aedes albopictus</i> mosquitoes. Emerging Microbes and Infections, 2019, 8, 1668-1678.	6.5	37
49	Low Zika Virus Seroprevalence in Vientiane, Laos, 2003–2015. American Journal of Tropical Medicine and Hygiene, 2019, 100, 639-642.	1.4	27
50	SuPReMe: a rapid reverse genetics method to generate clonal populations of recombinant RNA viruses. Emerging Microbes and Infections, 2018, 7, 1-11.	6.5	14
51	Evolution of Chikungunya virus in mosquito cells. Scientific Reports, 2018, 8, 16175.	3.3	4
52	Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies. Virology Journal, 2018, 15, 192.	3.4	55
53	Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. Nature Communications, 2018, 9, 4013.	12.8	54
54	Experimental Adaptation of the Yellow Fever Virus to the Mosquito Aedes albopictus and Potential risk of urban epidemics in Brazil, South America. Scientific Reports, 2018, 8, 14337.	3.3	28

#	Article	IF	CITATIONS
55	Live Zika virus chimeric vaccine candidate based on a yellow fever 17-D attenuated backbone. Emerging Microbes and Infections, 2018, 7, 1-12.	6.5	17
56	Detection of Japanese Encephalitis Virus RNA in Human Throat Samples in Laos $\hat{a} \in A$ Pilot study. Scientific Reports, 2018, 8, 8018.	3.3	13
57	Comparison of chikungunya viruses generated using infectious clone or the Infectious Subgenomic Amplicons (ISA) method in Aedes mosquitoes. PLoS ONE, 2018, 13, e0199494.	2.5	4
58	Exploratory re-encoding of yellow fever virus genome: new insights for the design of live-attenuated viruses. Virus Evolution, 2018, 4, vey021.	4.9	8
59	Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection. Viruses, 2018, 10, 268.	3.3	126
60	What Does the Future Hold for Yellow Fever Virus? (I). Genes, 2018, 9, 291.	2.4	34
61	Molecular determinants of Yellow Fever Virus pathogenicity in Syrian Golden Hamsters: one mutation away from virulence. Emerging Microbes and Infections, 2018, 7, 1-18.	6.5	12
62	Re-visiting the evolution, dispersal and epidemiology of Zika virus in Asia. Emerging Microbes and Infections, 2018, 7, 1-8.	6.5	39
63	What Does the Future Hold for Yellow Fever Virus? (II). Genes, 2018, 9, 425.	2.4	32
64	Molecular epidemiology of dengue viruses in three provinces of Lao PDR, 2006-2010. PLoS Neglected Tropical Diseases, 2018, 12, e0006203.	3.0	17
65	Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. PLoS Medicine, 2018, 15, e1002535.	8.4	108
66	Zika virus epidemiology in Bolivia: A seroprevalence study in volunteer blood donors. PLoS Neglected Tropical Diseases, 2018, 12, e0006239.	3.0	50
67	Haiku: New paradigm for the reverse genetics of emerging RNA viruses. PLoS ONE, 2018, 13, e0193069.	2.5	7
68	Development of an improved RT-qPCR Assay for detection of Japanese encephalitis virus (JEV) RNA including a systematic review and comprehensive comparison with published methods. PLoS ONE, 2018, 13, e0194412.	2.5	32
69	Implementation of a non-human primate model of Ebola disease: Infection of Mauritian cynomolgus macaques and analysis of virus populations. Antiviral Research, 2017, 140, 95-105.	4.1	13
70	Low seroprevalence of Zika virus in Cameroonian blood donors. Brazilian Journal of Infectious Diseases, 2017, 21, 481-483.	0.6	41
71	Zika virus in asymptomatic blood donors in Martinique. Blood, 2017, 129, 263-266.	1.4	108
72	New reverse genetics and transfection methods to rescue arboviruses in mosquito cells. Scientific Reports, 2017, 7, 13983.	3.3	22

#	Article	IF	CITATIONS
73	Acute respiratory infections in hospitalized children in Vientiane, Lao PDR – the importance of Respiratory Syncytial Virus. Scientific Reports, 2017, 7, 9318.	3.3	16
74	Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8847-8852.	7.1	89
75	High Zika Virus Seroprevalence in Salvador, Northeastern Brazil Limits the Potential for Further Outbreaks. MBio, 2017, 8, .	4.1	183
76	Emerging arboviruses: Why today?. One Health, 2017, 4, 1-13.	3.4	326
77	Aetiology of acute meningoencephalitis in Cambodian children, 2010–2013. Emerging Microbes and Infections, 2017, 6, 1-8.	6.5	33
78	Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	59
79	Association between reported aetiology of central nervous system infections and the speciality of study investigators—a bias compartmental syndrome?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2017, 111, 579-583.	1.8	2
80	Evidence for Congenital Zika Virus Infection From Neutralizing Antibody Titers in Maternal Sera, Northeastern Brazil. Journal of Infectious Diseases, 2017, 216, 1501-1504.	4.0	23
81	Epidemiology of Chikungunya Virus Outbreaks in Guadeloupe and Martinique, 2014: An Observational Study in Volunteer Blood Donors. PLoS Neglected Tropical Diseases, 2017, 11, e0005254.	3.0	44
82	Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Neglected Tropical Diseases, 2017, 11, e0005389.	3.0	153
83	Isolation and full-genome sequences of Japanese encephalitis virus genotype I strains from Cambodian human patients, mosquitoes and pigs. Journal of General Virology, 2017, 98, 2287-2296.	2.9	16
84	Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Medicine, 2016, 13, e1001967.	8.4	382
85	Serological Evidence of Contrasted Exposure to Arboviral Infections between Islands of the Union of Comoros (Indian Ocean). PLoS Neglected Tropical Diseases, 2016, 10, e0004840.	3.0	22
86	Simple reverse genetics systems for Asian and African Zika viruses. Scientific Reports, 2016, 6, 39384.	3.3	51
87	Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity. Journal of Hepatology, 2016, 65, 499-508.	3.7	99
88	Evidence of Sexual Transmission of Zika Virus. New England Journal of Medicine, 2016, 374, 2195-2198.	27.0	632
89	How Did Zika Virus Emerge in the Pacific Islands and Latin America?. MBio, 2016, 7, .	4.1	119
90	G + C content differs in conserved and variable amino acid residues of flaviviruses and other evolutionary groups. Infection, Genetics and Evolution, 2016, 45, 332-340.	2.3	7

#	Article	IF	Citations
91	Importance of mosquito "quasispecies―in selecting an epidemic arthropod-borne virus. Scientific Reports, 2016, 6, 29564.	3.3	21
92	Novel 2-phenyl-5-[(E)-2-(thiophen-2-yl)ethenyl]-1,3,4-oxadiazole and 3-phenyl-5-[(E)-2-(thiophen-2-yl)ethenyl]-1,2,4-oxadiazole derivatives as dengue virus inhibitors targeting NS5 polymerase. European Journal of Medicinal Chemistry, 2016, 109, 146-156.	5 . 5	54
93	Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. Clinical Pharmacokinetics, 2016, 55, 907-923.	3.5	135
94	Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. New England Journal of Medicine, 2016, 374, 33-42.	27.0	457
95	Isolation, full genomic characterization and neutralization-based human seroprevalence of Medjerda Valley virus, a novel sandfly-borne phlebovirus belonging to the Salehabad virus complex in northern Tunisia. Journal of General Virology, 2016, 97, 602-610.	2.9	19
96	Background review for diagnostic test development for Zika virus infection. Bulletin of the World Health Organization, 2016, 94, 574-584D.	3.3	104
97	Effect of Chemical Stabilizers on the Thermostability and Infectivity of a Representative Panel of Freeze Dried Viruses. PLoS ONE, 2015, 10, e0118963.	2.5	26
98	Risk Factors Associated with Ebola and Marburg Viruses Seroprevalence in Blood Donors in the Republic of Congo. PLoS Neglected Tropical Diseases, 2015, 9, e0003833.	3.0	26
99	Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections. PLoS ONE, 2015, 10, e0130378.	2.5	58
100	"ISA-Lation―of Single-Stranded Positive-Sense RNA Viruses from Non-Infectious Clinical/Animal Samples. PLoS ONE, 2015, 10, e0138703.	2.5	22
101	A secondary dengue 4 infection in a traveler returning from Haiti confirmed by virus isolation, complete genome sequencing and neutralisation assay: A brief report. Travel Medicine and Infectious Disease, 2015, 13, 94-97.	3.0	2
102	Prospective and retrospective evaluation of the Cepheid Xpert \hat{A}^{\odot} Flu/RSV XC assay for rapid detection of influenza A, influenza B, and respiratory syncytial virus. Diagnostic Microbiology and Infectious Disease, 2015, 81, 256-258.	1.8	53
103	Favipiravir for children with Ebola. Lancet, The, 2015, 385, 603-604.	13.7	43
104	Dose regimen of favipiravir for Ebola virus disease. Lancet Infectious Diseases, The, 2015, 15, 150-151.	9.1	86
105	Attenuation of Tick-Borne Encephalitis Virus Using Large-Scale Random Codon Re-encoding. PLoS Pathogens, 2015, 11, e1004738.	4.7	37
106	Isolation, Genetic Characterization, and Seroprevalence of Adana Virus, a Novel Phlebovirus Belonging to the Salehabad Virus Complex, in Turkey. Journal of Virology, 2015, 89, 4080-4091.	3.4	51
107	Chikungunya Virus Transmission Potential by Local Aedes Mosquitoes in the Americas and Europe. PLoS Neglected Tropical Diseases, 2015, 9, e0003780.	3.0	99
108	Caribbean and La Réunion Chikungunya Virus Isolates Differ in Their Capacity To Induce Proinflammatory Th1 and NK Cell Responses and Acute Joint Pathology. Journal of Virology, 2015, 89, 7955-7969.	3.4	95

#	Article	IF	CITATIONS
109	Rapid next-generation sequencing of dengue, EV-A71 and RSV-A viruses. Journal of Virological Methods, 2015, 226, 7-14.	2.1	18
110	Ecuador Paraiso Escondido Virus, a New Flavivirus Isolated from New World Sand Flies in Ecuador, Is the First Representative of a Novel Clade in the Genus Flavivirus. Journal of Virology, 2015, 89, 11773-11785.	3.4	31
111	Ebola virus dynamics in mice treated with favipiravir. Antiviral Research, 2015, 123, 70-77.	4.1	57
112	How many patients with anti-JEV IgM in cerebrospinal fluid really have Japanese encephalitis?. Lancet Infectious Diseases, The, 2015, 15, 1376-1377.	9.1	28
113	Flavivirus reverse genetic systems, construction techniques and applications: A historical perspective. Antiviral Research, 2015, 114, 67-85.	4.1	100
114	Thiazolidone derivatives as inhibitors of chikungunya virus. European Journal of Medicinal Chemistry, 2015, 89, 172-178.	5 . 5	52
115	New Insights into Flavivirus Evolution, Taxonomy and Biogeographic History, Extended by Analysis of Canonical and Alternative Coding Sequences. PLoS ONE, 2015, 10, e0117849.	2.5	139
116	First Reported Chikungunya Fever Outbreak in the Republic of Congo, 2011. PLoS ONE, 2014, 9, e115938.	2.5	58
117	Estimating the Burden of Japanese Encephalitis Virus and Other Encephalitides in Countries of the Mekong Region. PLoS Neglected Tropical Diseases, 2014, 8, e2533.	3.0	52
118	A Sero-epidemiological Study of Arboviral Fevers in Djibouti, Horn of Africa. PLoS Neglected Tropical Diseases, 2014, 8, e3299.	3.0	54
119	Evaluation of Antiviral Efficacy of Ribavirin, Arbidol, and T-705 (Favipiravir) in a Mouse Model for Crimean-Congo Hemorrhagic Fever. PLoS Neglected Tropical Diseases, 2014, 8, e2804.	3.0	138
120	Presence of sandfly-borne phleboviruses of two antigenic complexes (Sandfly fever Naples virus and) Tj ETQq0 0 microneutralisation-based seroprevalence study in dogs. Parasites and Vectors, 2014, 7, 476.	0 rgBT /Ov 2.5	verlock 10 Tf : 18
121	Development of generic Taqman PCR and RT-PCR assays for the detection of DNA and mRNA of \hat{l}^2 -actin-encoding sequences in a wide range of animal species. Journal of Virological Methods, 2014, 202, 101-105.	2.1	24
122	Chikungunya in the Americas. Lancet, The, 2014, 383, 514.	13.7	466
123	Prospective detection of chikungunya virus in blood donors, Caribbean 2014. Blood, 2014, 123, 3679-3681.	1.4	51
124	Single-stranded positive-sense RNA viruses generated in days using infectious subgenomic amplicons. Journal of General Virology, 2014, 95, 2462-2467.	2.9	75
125	Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. Journal of Antimicrobial Chemotherapy, 2014, 69, 2770-2784.	3.0	187
126	Novel flaviviruses from mosquitoes: Mosquito-specific evolutionary lineages within the phylogenetic group of mosquito-borne flaviviruses. Virology, 2014, 464-465, 320-329.	2.4	56

#	Article	IF	Citations
127	Highly Diverse Morbillivirus-Related Paramyxoviruses in Wild Fauna of the Southwestern Indian Ocean Islands: Evidence of Exchange between Introduced and Endemic Small Mammals. Journal of Virology, 2014, 88, 8268-8277.	3.4	39
128	Influenza C virus high seroprevalence rates observed in 3 different population groups. Journal of Infection, 2014, 69, 182-189.	3.3	27
129	Widespread circulation of a new echovirus 30 variant causing aseptic meningitis and non-specific viral illness, South-East France, 2013. Journal of Clinical Virology, 2014, 61, 118-124.	3.1	33
130	SYBR Green Real-Time PCR for the Detection of All Enterovirus-A71 Genogroups. PLoS ONE, 2014, 9, e89963.	2.5	5
131	Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy. Antiviral Research, 2013, 99, 345-370.	4.1	388
132	Causes of non-malarial fever in Laos: a prospective study. The Lancet Global Health, 2013, 1, e46-e54.	6.3	197
133	Co-Circulation of Toscana Virus and Punique Virus in Northern Tunisia: A Microneutralisation-Based Seroprevalence Study. PLoS Neglected Tropical Diseases, 2013, 7, e2429.	3.0	33
134	Random Codon Re-encoding Induces Stable Reduction of Replicative Fitness of Chikungunya Virus in Primate and Mosquito Cells. PLoS Pathogens, 2013, 9, e1003172.	4.7	63
135	Molecular evolution of the insect-specific flaviviruses. Journal of General Virology, 2012, 93, 223-234.	2.9	141
136	Intense Co-Circulation of Non-Influenza Respiratory Viruses during the First Wave of Pandemic Influenza pH1N1/2009: A Cohort Study in Reunion Island. PLoS ONE, 2012, 7, e44755.	2.5	34
137	RNA and DNA Bacteriophages as Molecular Diagnosis Controls in Clinical Virology: A Comprehensive Study of More than 45,000 Routine PCR Tests. PLoS ONE, 2011, 6, e16142.	2.5	121
138	Nonstructural NS1 proteins of several mosquito-borne Flavivirus do not inhibit TLR3 signaling. Virology, 2010, 404, 319-330.	2.4	40
139	Genomics and evolution of Aedes-borne flaviviruses. Journal of General Virology, 2010, 91, 87-94.	2.9	74
140	The Crystal Structures of Chikungunya and Venezuelan Equine Encephalitis Virus nsP3 Macro Domains Define a Conserved Adenosine Binding Pocket. Journal of Virology, 2009, 83, 6534-6545.	3.4	195
141	Infectious Clones of Chikungunya Virus (La Réunion Isolate) for Vector Competence Studies. Vector-Borne and Zoonotic Diseases, 2006, 6, 325-337.	1.5	183
142	Origins, evolution, and vectorâ§,host coadaptations within the Genus Flavivirus. Advances in Virus Research, 2003, 59, 277-314.	2.1	163
143	Evolution, epidemiology, and dispersal of flaviviruses revealed by molecular phylogenies. Advances in Virus Research, 2001, 57, 71-103.	2.1	89
144	Phylogenetic relationships of flaviviruses correlate with their epidemiology, disease association and biogeography. Journal of General Virology, 2001, 82, 1867-1876.	2.9	271